```html

Severe Acute Respiratory Syndrome (SARS)

Overview

Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the SARS‑associated coronavirus (SARS‑CoV). First identified in November 2002 in the Guangdong province of China, the disease rapidly spread to 26 countries before the World Health Organization (WHO) declared the outbreak contained in July 2003.

Key points:

• Agent: SARS‑CoV, a member of the betacoronavirus family.
• Incubation period: Usually 2–10 days (median ≈ 5 days).
• Population affected: All ages can be infected, but adults > 30 years and people with underlying chronic diseases tend to develop more severe illness.
• Prevalence: The 2002‑2003 outbreak resulted in 8,098 reported cases and 774 deaths (case‑fatality rate ≈ 9.6 %). No sustained community transmission has been reported since 2004, but sporadic laboratory‑associated infections have occurred, underscoring the need for continued vigilance.

Although SARS is not currently circulating globally, understanding the disease remains critical because the same virus family caused the COVID‑19 pandemic. Lessons learned from SARS have shaped modern infection‑control practices and vaccine research.

Symptoms

Symptoms typically appear within 2–10 days after exposure and progress in three phases: prodromal, respiratory, and recovery (or deterioration). Not every patient experiences all signs.

Prodromal (early) symptoms

• Fever: ≥38 °C (100.4 °F), often the first sign.
• Chills & rigors
• Headache – usually non‑localized.
• Myalgia (muscle aches) and fatigue.
• Sore throat or hoarseness.

Respiratory phase

• Dry, non‑productive cough – may become productive as disease progresses.
• Shortness of breath (dyspnea), especially on exertion.
• Chest pain or tightness.
• Breathing sounds: crackles (rales) heard on auscultation.

Other possible manifestations

• Diarrhea (≈ 30 % of patients).
• Nausea or vomiting.
• Loss of appetite.
• Confusion or altered mental status in severe cases (often related to hypoxia).

Severe disease may lead to acute respiratory distress syndrome (ARDS), requiring supplemental oxygen or mechanical ventilation.

Causes and Risk Factors

Cause

SARS is caused by SARS‑CoV, a zoonotic coronavirus that likely originated in bats and reached humans through an intermediate animal host (civet cats were implicated in the 2002‑03 outbreak). The virus spreads primarily via respiratory droplets, but can also be transmitted through direct contact with contaminated surfaces (fomites) and, less commonly, aerosolized particles in close‑confined settings.

Risk Factors

• Close contact with an infected person: household members, healthcare workers, or anyone sharing a confined space.
• Occupational exposure: frontline medical staff, laboratory personnel handling SARS‑CoV, and animal market workers.
• Underlying health conditions: chronic lung disease (COPD, asthma), cardiovascular disease, diabetes, hypertension, immunosuppression, and obesity increase risk of severe disease.
• Age: Adults > 50 years have higher case‑fatality rates (≈ 15 %) compared with younger adults (≈ 5 %).
• Smoking: Impairs mucociliary clearance and lung immunity, raising susceptibility.

Diagnosis

Because early symptoms overlap with influenza and other respiratory infections, a high index of suspicion is essential, especially after known exposure.

Clinical evaluation

• Detailed travel and exposure history (e.g., visits to affected regions, contact with known cases).
• Physical exam focusing on temperature, respiratory rate, oxygen saturation (SpO₂), and lung auscultation.

Laboratory tests

• RT‑PCR (reverse‑transcription polymerase chain reaction): Detects viral RNA from nasopharyngeal or oropharyngeal swabs, sputum, or lower‑respiratory samples. Considered the gold standard; sensitivity improves with repeated testing.
• Serology: IgM/IgG antibody testing becomes useful ≥10 days after symptom onset to confirm past infection, but is not reliable for acute diagnosis.
• Complete blood count (CBC): Often shows lymphopenia (low lymphocyte count) and mild thrombocytopenia.
• Inflammatory markers: Elevated CRP, ferritin, and LDH may indicate severe disease.

Imaging

• Chest X‑ray: May reveal bilateral infiltrates, ground‑glass opacities, or consolidation, especially in later stages.
• High‑resolution CT scan: More sensitive; typical findings include peripheral ground‑glass opacities, multilobar involvement, and “crazy‑paving” patterns.

Diagnostic criteria (WHO, 2003)

1. Fever ≥38 °C plus respiratory symptoms (cough or dyspnea).
2. Epidemiologic link (travel to area with SARS transmission or close contact with a probable/confirmed case).
3. Laboratory confirmation by RT‑PCR or serology.

Treatment Options

There is no specific antiviral therapy proven to cure SARS. Management is largely supportive and focused on preventing complications.

Supportive care

• Oxygen therapy: Nasal cannula, face mask, or high‑flow oxygen to maintain SpO₂ ≥ 94 %.
• Mechanical ventilation: Indicated for ARDS or worsening hypoxemia. Lung‑protective ventilation strategies (low tidal volume, permissive hypercapnia) are recommended.
• Fluid management: Conservative strategy to avoid pulmonary edema.
• Nutritional support: Early enteral feeding when feasible.

Pharmacologic approaches (investigational)

• Ribavirin: Used empirically in the 2003 outbreak but later studies showed limited benefit and significant toxicity.
• Protease inhibitors (e.g., lopinavir/ritonavir): In vitro activity; some clinicians used them during the outbreak, but randomized data are lacking.
• Corticosteroids: High‑dose steroids were administered to reduce inflammation, but they can delay viral clearance and increase secondary infections. Current guidance advises against routine use; may be considered in refractory ARDS after weighing risks.
• Interferon‑β: Investigational; limited data.

Adjunctive therapies

• Prophylactic broad‑spectrum antibiotics only if bacterial superinfection is suspected.
• Anticoagulation in patients with immobilization or elevated D‑dimer to prevent venous thromboembolism.

Clinical trials & research

Since SARS‑CoV shares structural features with SARS‑CoV‑2, many agents tested for COVID‑19 (e.g., monoclonal antibodies, remdesivir) are being retrospectively evaluated for SARS. No FDA‑approved drug exists specifically for SARS as of 2026.

Living with Severe Acute Respiratory Syndrome (SARS)

Although new infections are rare, people who have recovered may experience lingering effects, especially after severe disease.

Post‑recovery monitoring

• Follow‑up chest imaging 4–6 weeks after discharge to ensure resolution of infiltrates.
• Pulmonary function tests (spirometry, DLCO) if dyspnea persists.
• Psychological support: anxiety, post‑traumatic stress, and depression are reported in up to 30 % of survivors.

Daily management tips

• Stay hydrated – aim for ≥ 2 L of fluid daily unless restricted by heart/kidney disease.
• Exercise cautiously: Begin with low‑impact activities (walking, gentle stretching) and progress as tolerated; avoid high‑intensity workouts until lung capacity is re‑established.
• Vaccinations: Keep up‑to‑date with influenza, COVID‑19, pneumococcal, and other recommended vaccines to reduce secondary infection risk.
• Smoking cessation: Eliminates a major risk factor for respiratory complications.
• Nutrition: Prioritize protein‑rich foods (lean meats, legumes, dairy) to support tissue repair.
• Sleep hygiene: Aim for 7–9 hours/night; poor sleep impairs immune recovery.

Prevention

Because community transmission is currently absent, most preventive measures focus on outbreak preparedness and protecting high‑risk groups.

• Hand hygiene: Wash hands with soap for ≥20 seconds or use an alcohol‑based sanitizer (≥60 % ethanol).
• Respiratory etiquette: Cover coughs/sneezes with a tissue or elbow; discard tissues promptly.
• Personal protective equipment (PPE) for healthcare workers: N95/FFP2 respirators, eye protection, gloves, and gowns when caring for suspected or confirmed cases.
• Environmental cleaning: Regular disinfection of high‑touch surfaces with EPA‑approved agents.
• Travel precautions: Stay informed about alerts from WHO or CDC; avoid close contact with ill travelers from areas with known coronavirus activity.
• Isolation protocols: Patients with suspected SARS should be placed in a negative‑pressure isolation room; limit visitors.

Complications

If the infection progresses unchecked, several serious complications can arise:

• Acute respiratory distress syndrome (ARDS): The leading cause of mortality, characterized by severe hypoxemia and diffuse lung injury.
• Septic shock: Due to secondary bacterial infection or overwhelming viral inflammation.
• Multi‑organ failure: Kidney injury, hepatic dysfunction, and cardiac arrhythmias have been reported.
• Thromboembolic events: Deep‑vein thrombosis and pulmonary embolism, partly related to immobilization and inflammation.
• Long‑term pulmonary fibrosis: Persistent scarring can reduce lung capacity, causing chronic dyspnea.
• Psychiatric sequelae: Depression, anxiety, and post‑traumatic stress disorder (PTSD) affect up to one‑third of survivors.

When to Seek Emergency Care

References

• World Health Organization. Severe Acute Respiratory Syndrome (SARS) fact sheet. 2024. https://www.who.int
• Mayo Clinic. SARS (Severe Acute Respiratory Syndrome). 2023. https://www.mayoclinic.org
• Centers for Disease Control and Prevention. Severe Acute Respiratory Syndrome (SARS) – Clinical Guidance. 2022. https://www.cdc.gov
• National Institutes of Health. Coronavirus Disease 2002–2003 (SARS) – NIH Research Updates. 2021.
• Cleveland Clinic. SARS: Symptoms, Diagnosis, and Treatment. 2023.
• Peiris, J.S. et al. “Clinical progression and viral load in SARS.” N Engl J Med. 2003;348:1727‑1737.
• Lee, N. et al. “Long‑term complications of severe acute respiratory syndrome.” Thorax. 2005;60: 114–118.

```